CARDINAL HEALTH INC
For the period ended Dec 31, 2025. Filed Feb 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
| Period | Total Numberof SharesPurchased (1,2,3) | Average Price Paid per Share (2,3) | Total Number of SharesPurchasedas Part of Publicly Announced Programs (2,3,4) | ApproximateDollar Value ofShares That MayYet be PurchasedUnder the Program (4)(in millions) |
|---|---|---|---|---|
| October 2025 | 443,682 | $151.88 | 443,675 | $2,368 |
| November 2025 | 1,577,127 | 190.22 | 1,577,121 | 2,068 |
| December 2025 | 297,898 | 200.00 | 297,892 | 1,993 |
| Total | 2,318,707 | $184.15 | 2,318,688 | $1,993 |
(1)Reflects 7, 6, and 6 common shares purchased in October, November, and December 2025, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On November 3, 2025, we entered into an ASR program to purchase common shares for an aggregate purchase price of $375 million and received an initial delivery of 1.6 million common shares using a reference price of $190.22. The ASR program concluded on December 15, 2025 at a volume weighted average price per common share of $200.00 resulting in a final delivery of 0.3 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On August 13, 2025, we entered into an ASR program to purchase common shares for an aggregate purchase price of $375 million and received an initial delivery of 2.0 million common shares using a reference price of $148.12. The ASR program concluded on October 31, 2025 at a volume weighted average price per common share of $151.88 resulting in a final delivery of 0.4 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(4)On June 7, 2023, our Board of Directors approved a $3.5 billion share repurchase program, which will expire on December 31, 2027. As of December 31, 2025, we had $2.0 billion authorized for share repurchases remaining under this program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.